Kenneth P. Nephew

Blocking MAT2A-driven SAM synthesis in ovarian cancer cells prevents cisplatin-induced DNA hypermethylation, impairs DNA repair signaling, and blocks stem cell enrichment, sensitizing MTAP-proficient and MTAP-deficient lines.

This study shows that vitamin D signaling activation suppresses platinum-induced ovarian cancer stem cell plasticity, reducing stemness and tumor growth in vivo.

This paper shows that STING agonists combined with epigenetic drugs enhance necroptosis in TP53-mutated AML by activating STING and upregulating interferon-related genes.

This study examines methylome changes and immune cell shifts in SCLC patients treated with guadecitabine, revealing hypomethylation and altered immune profiles.

This study shows that extracellular vesicles from ovarian cancer stem cells or drug-resistant cells transfer stem-like properties and drug resistance to sensitive cells via EZH2 signaling.

This study identifies H3K9me3 methyltransferases as key drivers in glioblastoma, showing their association with prognosis, immune response, and drug response through multi-omics analysis.

This paper shows SUV39H1 is critical for maintaining glioblastoma stem cell properties and progression, and targeting it enhances chemotherapy effectiveness.

This study identifies HSF1 and MYC co-amplification in ovarian cancer and shows that targeting PLK1 is more effective in these cells, suggesting a potential precision medicine approach.

This study identifies ZNFX1 as a master regulator of epigenetically-induced pathogen mimicry and inflammasome signaling in ovarian cancer, linking its expression to disease progression and survival.

This paper shows that claudin-4 remodels nucleus-cell cycle interactions to maintain genome stability and resist genomic instability-inducing agents in ovarian cancer.

This study shows HSF1 suppresses CD8+ T cell infiltration in breast tumors by reducing CCL5 expression, thereby preventing immune-mediated tumor destruction.